DÄ internationalArchiveReferences
References

Review article

The Range and Scientific Value of Randomized Trials

Dtsch Arztebl Int 2017; 114: 635-40. DOI: 10.3238/arztebl.2017.0635

Lange, S; Sauerland, S; Lauterberg, J; Windeler, J

1.Savovic J, Jones H, Altman D, et al.: Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012; 16: 1–82 CrossRef MEDLINE
2.Blair E: Gold is not always good enough: the shortcomings of randomization when evaluating interventions in small heterogeneous samples. J Clin Epidemiol 2004; 57: 1219–22 CrossRef MEDLINE
3.Altman DG, Bland JM: Treatment allocation by minimisation. BMJ 2005; 330: 843 CrossRef MEDLINE PubMed Central
4.Zucker DR, Ruthazer R, Schmid CH: Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol 2010; 63: 1312–23 CrossRef MEDLINE PubMed Central
5.Chenot JF: Cluster-randomisierte Studien: eine wichtige Methode in der allgemeinmedizinischen Forschung. Z Evid Fortbild Qual Gesundhwes 2009; 103: 475–80 CrossRef
6.Kleist P: Studiendesigns mit unvollständiger Aufklärung der Versuchspersonen. Schweiz Ärztezeitung 2010; 91: 994–7 CrossRef
7.Food and Drug Administration. Adaptive design clinical trials for drugs and biologics – Draft guidance [online]. 02.2010 www.fda.gov/downloads/drugs/guidances/ucm201790.pdf (last accessed on 18 February 2017).
8.Bassler D, Montori VM, Briel M, et al.: Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it? Stat Methods Med Res 2013; 22: 159–68 CrossRef MEDLINE
9.Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM: Problems of stopping trials early. BMJ 2012; 344: e3863 CrossRef MEDLINE
10.Berry SM, Connor JT, Lewis RJ: The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313: 1619–20 CrossRef MEDLINE
11.Woodcock J, LaVange LM: Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377: 62–70 CrossRef MEDLINE
12.Renfro LA, Sargent DJ: Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017; 28: 34–43 MEDLINE
13.Roland M, Torgerson DJ: What are pragmatic trials? BMJ 1998; 316: 285 CrossRef MEDLINE PubMed Central
14.Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624–32 CrossRef MEDLINE
15.Sacristan JA, Soto J, Galende I, Hylan TR: Randomized database studies: a new method to assess drugs‘ effectiveness? J Clin Epidemiol 1998; 51: 713–5 MEDLINE
16.Lagerqvist B, Frobert O, Olivecrona GK, et al.: Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014; 371: 1111–20 CrossRef MEDLINE
17.Greenfield S, Kravitz R, Duan N, Kaplan SH: Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007; 120: 3–9 CrossRef MEDLINE
18.Ioannidis JP, Haidich AB, Pappa M, et al.: Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821–30 CrossRef MEDLINE
19.Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Bewertung und Auswertung von Studien bei seltenen Erkrankungen: Rapid Report; Auftrag MB13–01 (online). 05.09.2014 (IQWiG-Berichte; Band 241). www.iqwig.de/download/MB13–01_Rapid-Report_Studien-bei-seltenen-Erkrankungen.pdf (last accessed on 18 February 2017).
20.Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women‘s health initiative randomized controlled trial. JAMA 2002; 288: 321–33 CrossRef MEDLINE
21.Angus DC: Whether to intubate during cardiopulmonary resuscitation: conventional wisdom vs big data. JAMA 2017; 317: 477–8 CrossRef MEDLINE
22.Sarno G, Lagerqvist B, Frobert O, et al.: Lower risk of stent thrombosis and restenosis with unrestricted use of ‚new-generation‘ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33: 606–13 CrossRef MEDLINE
23.Anglemyer A, Horvath HT, Bero L: Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014; 4: MR000034 CrossRef
24.Furlan AD, Tomlinson G, Jadad AA, Bombardier C: Methodological quality and homogeneity influenced agreement between randomized trials and nonrandomized studies of the same intervention for back pain. J Clin Epidemiol 2008; 61: 209–31 CrossRef MEDLINE
25.Bundesverband Medizintechnologie (BVMed): 5-Punkte-Plan zur Nutzenbewertung von Medizintechnologien. Berlin: 2014. www.bvmed.de/de/versorgung/nutzenbewertung/5-punkte-nutzenbewertung (last accessed on 18 February 2017).
26.Sherman RE, Anderson SA, Dal Pan GJ, et al.: Real-world evidence—what is it and what can it tell us? N Engl J Med 2016; 375: 2293–7 CrossRef MEDLINE
27.Treasure T, Fallowfield L, Lees B: Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol 2010; 5: 203–6 CrossRef MEDLINE
28.Surgical & Interventional Trials Unit (SITU) DoSIS, Faculty of Medical Sciences UCL. PulMiCC Newsletter Issue 001 (online). 03.2015 . www.ucl.ac.uk/surgical-interventional-trials-unit/documents/trials_doc/pulmicc_doc/pulmicc_open/PULMICC_news_docs/PulMiCC_Newsletter__Issue_001__March_2015_.pdf
(last accessed on 18 February 2017)
29.Nenke MA, Haylock CL, Rankin W, et al.: Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial. Psychoneuroendocrinology 2015; 56: 157–67 CrossRef MEDLINE
30.Mitchell GK, Hardy JR, Nikles CJ, et al.: The effect of methylphenidate on fatigue in advanced cancer: an aggregated N-of-1 Trial. J Pain Symptom Manage 2015; 50: 289–96 CrossRef MEDLINE
31.Yusuf S, Lonn E, Pais P, et al.: Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016; 374: 2032–43 CrossRef CrossRef
32.Weltermann B, Kersting C, Viehmann A: Hypertension management in primary care. Dtsch Arztebl Int. 2016; 113: 167–74 VOLLTEXT
33.Bhatt DL, Stone GW, Mahaffey KW, et al.: Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303–13 CrossRef MEDLINE
34.James ND, Sydes MR, Clarke NW, et al.: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009; 103: 464–9 CrossRef MEDLINE
35.James ND, Sydes MR, Mason MD, et al.: Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012; 13: 549–58 CrossRef
36.Sydes MR, Parmar MK, Mason MD, et al.: Flexible trial design in practice—stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012; 13: 168 CrossRef MEDLINE PubMed Central
37.STAMPEDE: Systemic therapy in advancing or metastatic prostate cancer: Evaluation of drug efficacy. A multi-arm multi-stage randomised controlled trial. Version: 15.0 (online). 29.03.2016 www. stampedetrial.org/87548/87552/STAMPEDE_Protocol_v15.0_clean.pdf (last accessed on 18 February 2017).
38.Vestbo J, Leather D, Diar Bakerly N, et al.: Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med 2016; 375: 1253–60 CrossRef MEDLINE

Info

Figures and tables

    Figures and tables

    Authors

    Authors